2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
26
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
8
Adenocarcinoma
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
HER2-positive Breast Cancer
3
Advanced Solid Tumor
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm, Residual
2
Meningeal Carcinomatosis
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Interventions
Paclitaxel
115
Carboplatin
114
Cisplatin
46
Topotecan
43
Gemcitabine
31
Cyclophosphamide
31
Docetaxel
28
Bevacizumab
28
liposomal doxorubicin
27
Filgrastim
20
pembrolizumab
19
Peripheral Blood Stem Cell Transplantation
18
Taxes
15
Drug Therapy
15
Hyperthermic Intraperitoneal Chemotherapy
13
sargramostim
12
olaparib
12
Immunohistochemistry
11
Chemotherapy, Adjuvant
11
Surgical Procedures, Operative
10
Therapeutics
9
Flow Cytometry
9
Etoposide
9
oregovomab
8
niraparib
8
mirvetuximab soravtansine
8
Psychiatric Rehabilitation
8
Nivolumab
8
Amifostine
8
rucaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
trastuzumab deruxtecan
×
Clear all
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled